This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatmen
Completed
UCB PHARMA Inc. (US)
Phase 3
2006-01-01
This trial, evaluating the long-term safety and tolerability of brivaracetam will provide
subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive
treatment, the opportunity to receive open label brivaracetam treatment.
A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
Completed
UCB Pharma
Phase 2
2004-10-11
Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic
neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor
down-titration.
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
Completed
UCB Pharma
Phase 2
2005-11-07
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50
mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
Completed
UCB Pharma
Phase 3
2005-09-01
This trial, evaluating the long-term safety and tolerability of brivaracetam, will give
subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity
to continue the treatment. The study will also evaluate the maintenance of efficacy over time
of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures
(PGS).
A Study of Brivaracetam in Subjects With Partial Onset Seizures
Completed
UCB Pharma
Phase 2
2005-05-01
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150
mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
